Abstract
Mammalian cells cultured in the presence of the chemotherapeutic agent, methotrexate, develop resistance to this drug. Sometimes this is due to mutations in the gene for dihydrofolate reductase, the primary target of methotrexate. However, it has not been possible to link such polymorphism to resistance of neoplastic disease to therapy with methotrexate. Nevertheless, interest in this possibility lead to the introduction of many mutations into the cDNA for human DHFR by mutagenesis. Most of the corresponding enzyme variants have been expressed in Escherichia coli and characterized. Many mutations in codons for hydrophobic residues at the active site greatly decrease inhibition by methotrexate, and by the related substrate analogue, trimetrexate, while allowing the retention of considerable catalytic efficiency. Introduction of some of these mutants into mammalian cells by retroviral transfer provides substantial protection from toxic effects of the inhibitors, and has promise for the myeloprotection of patients receiving therapy with methotrexate or trimetrexate. Another potential use is in therapy for inherited disorders of hematopoiesis, where genetic modification of enough cells is a perennial problem. After transplantation ...Continue Reading
References
Sep 11, 1991·Nucleic Acids Research·M H PolymeropoulosC R Merril
Aug 20, 1991·Biochemistry·P D Thompson, J H Freisheim
Jul 10, 1990·Biochemistry·J T TsayR L Blakley
Dec 11, 1990·Nucleic Acids Research·R S McIvor, C C Simonsen
Jan 24, 1989·Biochemistry·S M HuangJ H Freisheim
May 17, 1988·Biochemistry·N J PrendergastJ H Freisheim
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·C C Simonsen, A D Levinson
Dec 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J H GoldieS Dedhar
Mar 10, 1995·The Journal of Biological Chemistry·W S LewisR L Blakley
Aug 23, 1994·Biochemistry·T NakanoR L Blakley
Feb 25, 1994·Gene·D BanerjeeJ R Bertino
Jan 1, 1993·Leukemia & Lymphoma·J R Bertino, E Göker
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A P DickerJ R Bertino
Sep 1, 1993·Archives of Biochemistry and Biophysics·S A MargosiakR L Blakley
Oct 3, 1996·The New England Journal of Medicine·R GorlickJ R Bertino
Nov 10, 1996·Human Gene Therapy·C A BlauT Papayannopoulou
Nov 14, 1997·Human Gene Therapy·J GalipeauB P Sorrentino
Dec 31, 1997·Human Gene Therapy·M PatelR L Blakley
Feb 11, 1998·Human Gene Therapy·M FlasshoveM A Moore
Citations
May 6, 2003·Journal of Molecular Biology·Edmunds Z Reineks, Anthony J Berdis
May 30, 2009·The Journal of Biological Chemistry·Jordan P VolpatoJoelle N Pelletier
Mar 21, 2002·The Lancet Oncology·Debabrata Banerjee, Joseph R Bertino
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·N UchidaI L Weissman
Apr 26, 2012·Leukemia & Lymphoma·M JoergerA J M Ferreri
Nov 30, 2007·Biochemical and Biophysical Research Communications·Ningwen TaiEdward Chu
Dec 6, 2005·European Journal of Pharmacology·Joslynn G AffleckVirginia K Walker
Feb 1, 2006·Expert Opinion on Therapeutic Patents·Giorgio V Scagliotti, Giovanni Selvaggi
Sep 18, 2007·Journal of Molecular Biology·Jordan P VolpatoJoelle N Pelletier
Aug 22, 2002·Nature Reviews. Cancer·Brian P Sorrentino
Jul 12, 2005·Oncogene·Cristina MoralesMiguel A Peinado
Apr 13, 2000·Biopharmaceutics & Drug Disposition·R PanW M Southerland
Apr 9, 2005·The Journal of Biological Chemistry·Nancy SkacelEmine Ercikan Abali
Jun 21, 2008·Journal of Biomolecular Screening·Elena FossatiJoelle N Pelletier
Jan 1, 2009·Clinical Medicine. Oncology·Anthony R VorthermsRobert P Doyle
Feb 5, 2009·Molecular Cancer Therapeutics·Cristina MoralesMiguel A Peinado
Jan 25, 2006·Molecular Cancer Therapeutics·Aparecida Maria FontesStanton L Gerson
Aug 22, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Junbiao WangAugusto Amici
Feb 11, 2005·Chemical Reviews·Ivan M KompisRudolf L Then